- A class action lawsuit has been filed against **Alto Neuroscience, Inc.** (NYSE: ANRO) on behalf of investors who purchased securities between **February 2, 2024, and October 22, 2024**.  **[1677077_181a0a8cff0a4205b2c95a2e1f17a8cd_0]** 
- The lawsuit alleges that Alto Neuroscience made false or misleading statements regarding the effectiveness of its drug candidate, **ALTO-100**, for treating major depressive disorder (MDD), overstating its clinical, regulatory, and commercial prospects.  **[1677077_181a0a8cff0a4205b2c95a2e1f17a8cd_0]** 
- On **October 22, 2024**, Alto Neuroscience announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a nearly **70%** drop in the company's stock price.  **[1677077_181a0a8cff0a4205b2c95a2e1f17a8cd_0]** 
- Investors have until **September 19, 2025**, to file a lead plaintiff motion in the class action lawsuit.  **[1677077_181a0a8cff0a4205b2c95a2e1f17a8cd_0]**

Alto Neuroscience Faces Class Action Lawsuit Over ALTO-100 Trial Results

- A class action lawsuit has been filed against **Alto Neuroscience, Inc.** (NYSE: ANRO) for investors who purchased securities between **February 2, 2024 and October 22, 2024**.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]** 
- The lawsuit alleges that the company made false or misleading statements regarding its drug candidate, ALTO-100, which was less effective in treating Major Depressive Disorder (MDD) than represented, and that its prospects were overstated.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]** 
- On October 22, 2024, Alto Neuroscience announced that ALTO-100's Phase 2b trial did not meet its primary endpoint, causing the stock to fall nearly **70%**.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]** 
- Investors have until **September 19, 2025** to file a lead plaintiff motion.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]**

Alzamend Neuro (ALZN)